4DMedical Secures $150M to Fast-Track US Rollout of CT:VQ™ Technology
4DMedical Limited has raised $150 million through a well-supported institutional placement to accelerate the commercialisation of its innovative lung imaging product CT – VQ™ in the US market. The capital raise comes with minimal dilution and increased insider confidence.
- Institutional placement raises $150 million at $3.80 per share
- Limited dilution of 3.86% by repurposing previously issued shares
- Funds to accelerate US commercialisation of CT – VQ™ at leading medical centres
- CEO and CFO exercise options, increasing their shareholdings
- Pro forma cash position exceeds $200 million, supporting path to profitability
Capital Raise to Fuel US Expansion
4DMedical Limited (ASX, 4DX), a Melbourne-based medical technology company specialising in advanced respiratory imaging, has successfully completed a $150 million institutional placement. The raise, priced at $3.80 per share, attracted strong demand from both new global institutional investors and existing shareholders, underscoring confidence in the company’s growth trajectory.
The proceeds will primarily support the accelerated commercialisation of 4DMedical’s CT, VQ™ product in the United States, where the technology has already gained rapid adoption at prestigious academic medical centres including Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. This momentum follows the product’s recent FDA clearance, validating its clinical potential.
Strategic Use of Funds and Shareholder Support
The capital injection will be deployed across sales, marketing, business development, and customer support to drive further adoption in US health systems. Additionally, funds will bolster research and development efforts to expand the product portfolio and maintain technological leadership in pulmonary imaging.
Importantly, the placement was structured to limit dilution to existing shareholders to just 3.86%, achieved by repurposing 18.7 million shares previously issued to Alpha Investment Partners. This careful approach reflects management’s commitment to shareholder value while securing substantial new capital.
Leadership Confidence and Financial Strength
In a strong signal of confidence, CEO Andreas Fouras and CFO Julian Sutton exercised options ahead of the placement, increasing their shareholdings in the company. Post-raise, 4DMedical’s cash reserves exceed $200 million, providing a robust balance sheet to support the company’s path to profitability and future growth opportunities.
CEO Fouras highlighted the significance of the raise, "With a strong commercial pipeline and strategic partnerships such as Philips, we have the resources to drive CT, VQ™ to become the new standard in pulmonary imaging. We are only getting started."
Looking Ahead
4DMedical plans to hold an investor webinar on 19 January 2026 to discuss the capital raise and commercial strategy in more detail. As the company leverages its strengthened financial position, market watchers will be keen to track how quickly CT, VQ™ adoption expands beyond early academic centres into broader clinical use.
Bottom Line?
With $150 million secured and leadership doubling down, 4DMedical is poised to redefine lung imaging in the US; and investors will be watching closely.
Questions in the middle?
- How quickly will CT, VQ™ expand beyond initial academic medical centres?
- What impact will strategic partnerships, like with Philips, have on commercial growth?
- How will the company balance R&D investment with the push toward profitability?
